Search hospitals > Nova Scotia > HALIFAX
Queen Elizabeth II Health Sciences Centre
Claim this profileHALIFAX, Nova Scotia B3H 2Y9
Global Leader in Lymphoma
Global Leader in Leukemia
Conducts research for Breast Cancer
Conducts research for Multiple Myeloma
Conducts research for Plasma Cell Neoplasms
372 reported clinical trials
31 medical researchers
Summary
Queen Elizabeth II Health Sciences Centre is a medical facility located in HALIFAX, Nova Scotia. This center is recognized for care of Lymphoma, Leukemia, Breast Cancer, Multiple Myeloma, Plasma Cell Neoplasms and other specialties. Queen Elizabeth II Health Sciences Centre is involved with conducting 372 clinical trials across 336 conditions. There are 31 research doctors associated with this hospital, such as David P. Lee, MD, Ivan Wong, MD, Ricardo Rendon, MD, and Sudeep Shivakumar, MD.Area of expertise
1Lymphoma
Global LeaderStage IV
Stage III
13q positive
2Leukemia
Global LeaderPhiladelphia chromosome negative
hepatitis B DNA negative
13q positive
Top PIs
David P. Lee, MDStanford Hospital and Clinics6 years of reported clinical research
Studies High Blood Pressure
Studies Vascular Disease
10 reported clinical trials
15 drugs studied
Ivan Wong, MDNova Scotia Health Authority3 years of reported clinical research
Studies Rotator Cuff Tears
Studies Osteoarthritis
7 reported clinical trials
12 drugs studied
Ricardo Rendon, MDQueen Elizabeth II Health Sciences Centre4 years of reported clinical research
Studies Prostate Cancer
Studies Non-Muscle Invasive Bladder Cancer
6 reported clinical trials
13 drugs studied
Sudeep Shivakumar, MDQueen Elizabeth II Health Sciences Centre6 years of reported clinical research
Studies Deep Vein Thrombosis
Studies Blood Clot
5 reported clinical trials
8 drugs studied
Clinical Trials running at Queen Elizabeth II Health Sciences Centre
Breast Cancer
Lymphoma
Leukemia
Acute Leukemia
Inflammatory Bowel Disease
Prostate Cancer
Pancreatic Cancer
Deep Vein Thrombosis
Blood Clot
Traumatic Brain Injury
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
This trial is testing a drug called sacituzumab govitecan-hziy, which targets and kills cancer cells. It focuses on patients with advanced triple-negative breast cancer who have limited treatment options. The drug works by attaching to cancer cells and releasing a substance that kills them. Sacituzumab govitecan-hziy is an FDA-approved treatment for metastatic triple-negative breast cancer, especially for patients who have already tried other treatments.
Recruiting4 awards Phase 3
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
This trial compares the effectiveness of a combination of two drugs, SG and pembrolizumab, in patients with advanced triple-negative breast cancer. SG targets and kills cancer cells with chemotherapy, while pembrolizumab helps the immune system attack the cancer. Pembrolizumab has been shown to improve survival in various cancers, including triple-negative breast cancer, when used alone or in combination with other treatments.
Recruiting4 awards Phase 3
Omitting Radiation Therapy
for Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Queen Elizabeth II Health Sciences Centre?
Queen Elizabeth II Health Sciences Centre is a medical facility located in HALIFAX, Nova Scotia. This center is recognized for care of Lymphoma, Leukemia, Breast Cancer, Multiple Myeloma, Plasma Cell Neoplasms and other specialties. Queen Elizabeth II Health Sciences Centre is involved with conducting 372 clinical trials across 336 conditions. There are 31 research doctors associated with this hospital, such as David P. Lee, MD, Ivan Wong, MD, Ricardo Rendon, MD, and Sudeep Shivakumar, MD.
Where is Queen Elizabeth II Health Sciences Centre located?
The Queen Elizabeth II Health Sciences Centre, situated in downtown Halifax, Nova Scotia, Canada, encompasses two main campuses: the Victoria site and the Halifax Infirmary site. The Victoria site houses the Nova Scotia Rehabilitation Centre, Bethune, Mackenzie, Centre for Clinical Research, Dickson, Victoria, and Centennial buildings. Meanwhile, the Halifax Infirmary site is comprised of the Halifax Infirmary, Charles V. Keating Emergency and Trauma Centre, Abbie J. Lane Memorial, and Camp Hill Veteran's Memorial buildings, with the emergency department located at the south end of the Halifax Infirmary site.
Who should I call to ask about financial aid or insurance network?
The Queen Elizabeth II Health Sciences Centre offers the QEII Patient Assistance Fund, granting up to $1000 to eligible patients for expenses such as rent, mortgage, lodging, home utilities, and other medical-related costs. For detailed information on financial assistance and insurance, contact the hospital directly at their main switchboard (902-473-2700) or patient switchboard (902-473-1510). Further details on the hospital's financial assistance policy and application process are available on The Queen's Health System website.
What insurance does Queen Elizabeth II Health Sciences Centre accept?
The Queen Elizabeth II Health Sciences Centre in Nova Scotia, Canada, is a leading multi-campus teaching and research organization. It offers specialized medical treatments, innovative therapies, and is affiliated with the Dalhousie University Faculty of Medicine. Patients should contact their insurance company for current coverage information at the Queen Elizabeth II Health Sciences Centre.
What awards or recognition has Queen Elizabeth II Health Sciences Centre received?
The Queen Elizabeth II Health Sciences Centre Foundation, located in Halifax, Nova Scotia, reported total revenues of $13.4 million in F2021, thanks to various campaigns and donations. It manages its investments through external investment managers, incurring fees based on market value. With funding reserves of $96 million, the Foundation can sustain its F2021 grant level for nearly eleven years.